Letters New group B meningococcus vaccine

No conspiracy regarding recommendation for a group B meningococcus vaccine

BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g2859 (Published 08 May 2014) Cite this as: BMJ 2014;348:g2859
  1. Andrew J Pollard, chair, Joint Committee on Vaccination and Immunisation (JCVI)1,
  2. Andrew Riordan, chair, meningococcal subcommittee of the JCVI, and acting chair (2013), JCVI2,
  3. Mary Ramsay, consultant epidemiologist and head3
  1. 1Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK
  2. 2Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
  3. 3Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, UK
  1. andrew.pollard{at}paediatrics.ox.ac.uk

Isaacs and McVernon highlight the importance and complexity of policy decision making for a group B meningococcal vaccine based on cost effectiveness.1

The health economic analysis for a group B meningococcal vaccine is difficult because of uncertainties about critical parameters that determine whether the vaccine meets the required threshold for cost effectiveness. Indeed, the first health economic model made available to the independent scientific committee that advises the UK Departments of Health—the Joint Committee on Vaccination and …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe